Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1993-10-08
1996-02-20
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514646, A61K 31135
Patent
active
054929334
ABSTRACT:
Methods and compositions are disclosed utilizing the optically pure R-isomers of terodiline or of the hydroxylated derivatives of terodiline, These compounds are potent drugs for the treatment of urinary incontinence, obstructive pulmonary disease and such other conditions as are related to the compounds' activity as anticholinergic agents.
REFERENCES:
patent: 3371014 (1968-02-01), Carlsson
patent: 4851404 (1989-07-01), Ohnishi et al.
patent: 4988730 (1991-01-01), Kurbinits et al.
Langtry and McTavish, et al "Terodiline, A review of its pharmological properties and therapeutic use" Drugs, vol. 40, No. 5, pp. 748-761. 1990.
Castenfors, et al, "Pilot Study of the effect of terodiline on obstruction Pulmonary disease", European Journal of Pharmocology, vol 8, pp. 197-201. 1975.
Noronha-Blob et al., "(+)-Terodiline: an M.sub.1 -selective muscarinic receptor antagonist. In vivo effects at muscarinic receptors mediating urinary bladder contraction, mydriasis and salivary secretion", European Journal of Pahrmacology 201: 135-142 (1991).
Bogentoft et al., "Worldwide safety profile of terodiline", Supplement to Urology 36(4): 58-62 (1990).
Enquist and Hermansson, "Separation of the enantiomers of .beta.-receptor blocking agents and other cationic drugs using a CHIRAL-AGP column", J. Chromat. 519: 285-298 (1990).
Noren et al., "Biotransformation of terodiline v. stereoselectivity in hydroxylation by human liver microsomes", Chem.-Biol. Interactions 71: 325-337 (1989).
Andersson et al., "Actions of terodiline, its isomers and main metabolite on isolated detrusor muscle from rabbit and man", Pharmacology & Toxicology 63: 390-395 (1988).
Helander et al., "The stereochemistry of N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butylamines", Acta Pharmaceutica Scandinavica B 42: 35-38 (1988).
Noren et al., "Biotransformation of terodiline. IV. Identification of unconjugated metabolites in dog and human urine", Acta Pharmaceutica Suecica 25(6): 281-292 (1988).
Lindeke et al., "Biotransformation of terodiline. III. Opposed stereoselectivity in the benzylic and aromatic hydroxylations in rat liver microsomes", Xenobiotica 17(11): 1269-1278 (1987).
Andersson, "Clinical pharmacology of terodiline", Scand. J. Urol. Nephrol. Supp. 87: 13-20 (1984).
Fischer-Rasmussen, "Evaluation of long-term safety and clinical benfit of terodiline in women with urgency/urge incontinence. A multicenter study", Scand. J. Urol. Nephrol. Suppl. 87: 35-47 (1984).
Rud et al., "Terodiline inhibition of human bladder contraction. Effects in vitro and in women with unstable bladder", Acta Pharmacol. et Toxicol. 46(1): 31-38 (1980).
Vessman and Sundwall, "Identification of hydroxylated metabolites of terodiline in aminal and man", Acta Pharmacol. Toxicol. 28:89 (1970).
Gray Nancy M.
Young James W.
Henley III Raymond
MacMillan Keith
Sepracor Inc.
LandOfFree
Methods and compositions for treating urinary incontinence and o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating urinary incontinence and o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating urinary incontinence and o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1356165